120 related articles for article (PubMed ID: 31310365)
1. An evaluation of different Cripto-1 antibodies and their variable results.
Gudbergsson JM; Duroux M
J Cell Biochem; 2020 Jan; 121(1):545-556. PubMed ID: 31310365
[TBL] [Abstract][Full Text] [Related]
2. A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth.
Ishii H; Zahra MH; Takayanagi A; Seno M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567764
[TBL] [Abstract][Full Text] [Related]
3. Cripto-1 localizes to dynamic and shed filopodia associated with cellular migration in glioblastoma cells.
Gudbergsson JM; Duroux M
Eur J Cell Biol; 2019 Dec; 98(5-8):151044. PubMed ID: 31543278
[TBL] [Abstract][Full Text] [Related]
4. Development of conformational antibodies targeting Cripto-1 with neutralizing effects in vitro.
Focà G; Iaccarino E; Focà A; Sanguigno L; Untiveros G; Cuevas-Nunez M; Strizzi L; Leonardi A; Ruvo M; Sandomenico A
Biochimie; 2019 Mar; 158():246-256. PubMed ID: 30703478
[TBL] [Abstract][Full Text] [Related]
5. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
Adkins HB; Bianco C; Schiffer SG; Rayhorn P; Zafari M; Cheung AE; Orozco O; Olson D; De Luca A; Chen LL; Miatkowski K; Benjamin C; Normanno N; Williams KP; Jarpe M; LePage D; Salomon D; Sanicola M
J Clin Invest; 2003 Aug; 112(4):575-87. PubMed ID: 12925698
[TBL] [Abstract][Full Text] [Related]
6. Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers.
Sandomenico A; Ruvo M
Curr Med Chem; 2019; 26(11):1994-2050. PubMed ID: 30207211
[TBL] [Abstract][Full Text] [Related]
7. Cripto monoclonal antibodies.
Hu XF; Xing PX
Drug News Perspect; 2005 Jun; 18(5):293-303. PubMed ID: 16193101
[TBL] [Abstract][Full Text] [Related]
8. Transfection with a CRIPTO anti-sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line.
Baldassarre G; Bianco C; Tortora G; Ruggiero A; Moasser M; Dmitrovsky E; Bianco AR; Ciardiello F
Int J Cancer; 1996 May; 66(4):538-43. PubMed ID: 8635871
[TBL] [Abstract][Full Text] [Related]
9. Targeting the embryonic gene Cripto-1 in cancer and beyond.
Bianco C; Salomon DS
Expert Opin Ther Pat; 2010 Dec; 20(12):1739-49. PubMed ID: 21073352
[TBL] [Abstract][Full Text] [Related]
10. Cripto as a target for cancer immunotherapy.
Hu XF; Xing PX
Expert Opin Ther Targets; 2005 Apr; 9(2):383-94. PubMed ID: 15934922
[TBL] [Abstract][Full Text] [Related]
11. New Anti-Nodal Monoclonal Antibodies Targeting the Nodal Pre-Helix Loop Involved in Cripto-1 Binding.
Focà A; Sanguigno L; Focà G; Strizzi L; Iannitti R; Palumbo R; Hendrix MJ; Leonardi A; Ruvo M; Sandomenico A
Int J Mol Sci; 2015 Sep; 16(9):21342-62. PubMed ID: 26370966
[TBL] [Abstract][Full Text] [Related]
12. An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours.
Kelly RK; Olson DL; Sun Y; Wen D; Wortham KA; Antognetti G; Cheung AE; Orozco OE; Yang L; Bailly V; Sanicola M
Eur J Cancer; 2011 Jul; 47(11):1736-46. PubMed ID: 21458984
[TBL] [Abstract][Full Text] [Related]
13. The role of Cripto-1 in the tumorigenesis and progression of oral squamous cell carcinoma.
Yoon HJ; Hong JS; Shin WJ; Lee YJ; Hong KO; Lee JI; Hong SP; Hong SD
Oral Oncol; 2011 Nov; 47(11):1023-31. PubMed ID: 21824804
[TBL] [Abstract][Full Text] [Related]
14. CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.
Zoni E; Chen L; Karkampouna S; Granchi Z; Verhoef EI; La Manna F; Kelber J; Pelger RCM; Henry MD; Snaar-Jagalska E; van Leenders GJLH; Beimers L; Kloen P; Gray PC; van der Pluijm G; Kruithof-de Julio M
Oncogene; 2017 Aug; 36(33):4739-4749. PubMed ID: 28394345
[TBL] [Abstract][Full Text] [Related]
15. Genetic variants modulating CRIPTO serum levels identified by genome-wide association study in Cilento isolates.
Ruggiero D; Nappo S; Nutile T; Sorice R; Talotta F; Giorgio E; Bellenguez C; Leutenegger AL; Liguori GL; Ciullo M
PLoS Genet; 2015 Jan; 11(1):e1004976. PubMed ID: 25629528
[TBL] [Abstract][Full Text] [Related]
16. The CRIPTO/FRL-1/CRYPTIC (CFC) domain of human Cripto. Functional and structural insights through disulfide structure analysis.
Foley SF; van Vlijmen HW; Boynton RE; Adkins HB; Cheung AE; Singh J; Sanicola M; Young CN; Wen D
Eur J Biochem; 2003 Sep; 270(17):3610-8. PubMed ID: 12919325
[TBL] [Abstract][Full Text] [Related]
17. Membrane-anchorage of Cripto protein by glycosylphosphatidylinositol and its distribution during early mouse development.
Minchiotti G; Parisi S; Liguori G; Signore M; Lania G; Adamson ED; Lago CT; Persico MG
Mech Dev; 2000 Feb; 90(2):133-42. PubMed ID: 10640699
[TBL] [Abstract][Full Text] [Related]
18. [Role of Cripto-1 protein in development and target therapy of breast cancer].
Lei T; Guo XJ; Fu L
Zhonghua Bing Li Xue Za Zhi; 2010 Jan; 39(1):66-8. PubMed ID: 20388407
[No Abstract] [Full Text] [Related]
19. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
20. Cripto, a member of the epidermal growth factor family, is over-expressed in human pancreatic cancer and chronic pancreatitis.
Friess H; Yamanaka Y; Büchler M; Kobrin MS; Tahara E; Korc M
Int J Cancer; 1994 Mar; 56(5):668-74. PubMed ID: 8314343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
